Oculis Holding is no longer the topical-retina story that carried the equity into the spring. In late May the two Phase 3 DIAMOND trials of the company's eye-drop candidate in diabetic macular edema missed the primary visual-acuity endpoint. Management then stopped the planned United States filing. What remains is a Swiss-listed clinical-stage company that has recast itself around a neuroprotective candidate in optic neuritis, plus a genotype-selected dry-eye program that is already more than halfway randomized. The share price now sits near the bottom of its yearly range, which is the market's verdict that the retinal franchise is gone and the replacement thesis is still unproven.
The cash pile is the reason the equity did not collapse to option value. Mid-year liquidity of $282 million funds operations well past the next two data events on management's own runway statement. That runway statement points into the second half of 2029. An at-the-market tap added $61 million of gross proceeds in the first half. Operating cash use of CHF 36 million over six months is consistent with a late-stage trial machine rather than a commercial build. The August asset purchase from Accure Therapeutics is the ownership move that matches the pivot. A small cash outlay plus contingent stock ends the licensed royalty stack on the lead asset.
The investment debate is whether the remaining two programs, plus a clean balance sheet, are worth more than cash plus a modest pipeline option. Year-end topline from the genotype-selected dry-eye trial is the first hard test. Enrollment in the optic-neuritis registrational study and the Accure close are the second. Does a post-miss neuroprotection story deserve a premium to cash, or is the market correctly treating both remaining assets as long-dated binaries?